Investigation Report on China Cinepazide Market, 2010-2019
Description
As a new generation of piperazine, cinepazide(cinepazide maleate) has been widely used in Europe and Japan. As calcium channel blocker, cinepazide can stop calcium from entering vascular smooth muscle cell and relax smooth muscle of cerebral vessel, coronary artery and peripheral vessel so as to relieve vasospasm, reduce vascular resistance, improve flexibility of red blood cell, increase blood circulation in cerebral vessel and improve microcirculation and brain metabolism. Cinepazide could also increase the number of cAMP by inhibiting cAMP phosphodiesterase and reduce oxygen consumption.
In Apr.2002, cinepazide of Beijing Hwellso Pharmaceutical Co., Ltd was approved to enter the market with two dosage forms of oral formulation and injection under the trade name of Kelinao. Currently, Kelinao is the only domestic brand for the treatment of cardiovascular diseases. And in 2009, cinepazide was included in the national medicare drug list.
Cinepazide maleate, after wide application, has gained the recognition of Chinese doctors and patients for the treatment of cerebral arteriosclerosis, transient ischemic attack, cerebral thrombosis, cerebral embolism, cerebral hemorrhage sequel and post-traumatic brain syndrome. Besides, due to its efficacy in cardiovascular diseases and peripheral vascular diseases, cinepazide maleate has become a leading product in cerebrovascular drug market. With ageing population, the number of cerebrovascular cases has kept rising, leading to a vast market for cinepazide.
According to CRI’s market survey, the annual sales value of cinepazide in sample hospitals has remained over CNY 400 million. Currently, cinepazide market in China is dominated by Beijing Hwellso Pharmaceutical Co., Ltd.
Readers can get at least the following information through this report:
As a new generation of piperazine, cinepazide(cinepazide maleate) has been widely used in Europe and Japan. As calcium channel blocker, cinepazide can stop calcium from entering vascular smooth muscle cell and relax smooth muscle of cerebral vessel, coronary artery and peripheral vessel so as to relieve vasospasm, reduce vascular resistance, improve flexibility of red blood cell, increase blood circulation in cerebral vessel and improve microcirculation and brain metabolism. Cinepazide could also increase the number of cAMP by inhibiting cAMP phosphodiesterase and reduce oxygen consumption.
In Apr.2002, cinepazide of Beijing Hwellso Pharmaceutical Co., Ltd was approved to enter the market with two dosage forms of oral formulation and injection under the trade name of Kelinao. Currently, Kelinao is the only domestic brand for the treatment of cardiovascular diseases. And in 2009, cinepazide was included in the national medicare drug list.
Cinepazide maleate, after wide application, has gained the recognition of Chinese doctors and patients for the treatment of cerebral arteriosclerosis, transient ischemic attack, cerebral thrombosis, cerebral embolism, cerebral hemorrhage sequel and post-traumatic brain syndrome. Besides, due to its efficacy in cardiovascular diseases and peripheral vascular diseases, cinepazide maleate has become a leading product in cerebrovascular drug market. With ageing population, the number of cerebrovascular cases has kept rising, leading to a vast market for cinepazide.
According to CRI’s market survey, the annual sales value of cinepazide in sample hospitals has remained over CNY 400 million. Currently, cinepazide market in China is dominated by Beijing Hwellso Pharmaceutical Co., Ltd.
Readers can get at least the following information through this report:
- market size of cinepazide in China
- competitive landscape of cinepazide market in China
- price of cinepazide made by different enterprises in China
- market outlook of cinepazide in China
- Pharmaceutical Manufacturers
- investors/research institutions interested in Chinese medicine market
- -any interest in Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF CINEPAZIDE
1.1 Indication
1.2 Market Status
2 MARKET PROFILE OF CINEPAZIDE IN CHINA
2.1 Patent and Approval Information of Cinepazide in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON CINEPAZIDE SALES IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR CINEPAZIDE MANUFACTURERS IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF CINEPAZIDE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF CINEPAZIDE IN CHINESE HOSPITALS IN 2014
7 MAJOR MANUFACTURERS OF CINEPAZIDE IN CHINESE MARKET, 2010-2014
8 MARKET OUTLOOK OF CINEPAZIDE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Information of Cinepazide in China
Chart Approval Information of Cinepazide in China
Chart Cinepazide Sales in China
Chart Sales Value of Cinepazide in China, 2010-2014
Chart Sales Value of Cinepazide in Some Regions in China, 2010-2014
Chart Sales Volume of Cinepazide in China, 2010-2014
Chart Sales Volume of Cinepazide in Some Regions in China, 2010-2014
Chart Sales Value and Market Share of Cinepazide Made by Beijing Hwellso in China,2010-2014
Chart Sales Volume and Market Share of Cinepazide Made by Beijing Hwellso in China,2010-2014
Chart Price of Cinepazide Made by Beijing Hwellso Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
1.1 Indication
1.2 Market Status
2 MARKET PROFILE OF CINEPAZIDE IN CHINA
2.1 Patent and Approval Information of Cinepazide in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON CINEPAZIDE SALES IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR CINEPAZIDE MANUFACTURERS IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF CINEPAZIDE IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF CINEPAZIDE IN CHINESE HOSPITALS IN 2014
7 MAJOR MANUFACTURERS OF CINEPAZIDE IN CHINESE MARKET, 2010-2014
8 MARKET OUTLOOK OF CINEPAZIDE IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
TABLE OF SELECTED CHARTS
Chart Patent Information of Cinepazide in China
Chart Approval Information of Cinepazide in China
Chart Cinepazide Sales in China
Chart Sales Value of Cinepazide in China, 2010-2014
Chart Sales Value of Cinepazide in Some Regions in China, 2010-2014
Chart Sales Volume of Cinepazide in China, 2010-2014
Chart Sales Volume of Cinepazide in Some Regions in China, 2010-2014
Chart Sales Value and Market Share of Cinepazide Made by Beijing Hwellso in China,2010-2014
Chart Sales Volume and Market Share of Cinepazide Made by Beijing Hwellso in China,2010-2014
Chart Price of Cinepazide Made by Beijing Hwellso Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
